A vaccine jointly developed by US drugmaker Pfizer and BioNTech which is claimed to be 90 percent effective in preventing Covid-19 infections has reached Phase 3 trials, announced the companies on Monday.
The company further informed that the vaccine showed improvement in the patients seven days after the second of two doses, and 28 days after the first.
” The first set of results from Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19″, Pfizer chairman and CEO Albert Bourla said in a statement.
“We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most, Bourla added.
The World Health Organization chief hailed as “encouraging” Pfizer and BioNTech’s announcement. “We welcome the encouraging vaccine news from @pfizer & @BioNTech_Group & salute all scientists & partners around the who are developing new safe, efficacious tools to beat #COVID19, WHO director Tedros Adhanom Ghebreyesus said in a tweet.